Lakefront Biotherapeutics (LKFT) Operating Leases (2019 - 2026)

As of Dec 31, 2025, Lakefront Biotherapeutics posted Operating Leases of $5.86 million, down 34.3% from the prior year.

• Operating Leases has a five-year compound annual growth rate of -25.9% (years ended Dec 2020 to Dec 2025).
• By year, Operating Leases came in at $8.92 million in the year ended Dec 31, 2024 (+67.7%), $5.32 million in the year ended Dec 31, 2023 (-65.6%), $15.48 million in the year ended Dec 31, 2022 (-33.4%) and $23.26 million in the year ended Dec 31, 2021 (-11.6%).
• The figure for the quarter ended Mar 31, 2026 ranks as the lowest quarterly Operating Leases since the quarter ended Mar 31, 2024.
• Year over year, Operating Leases has now declined in each of the last three quarters, with growth averaging 11.8% over the last six quarters.
• The high point for year-over-year Operating Leases in five years was the quarter ended Mar 31, 2025 (growth of 96.5%); the low point was the quarter ended Dec 31, 2023 (a decline of 64.5%).
• Per Business Quant data, the three quarters before the quarter ended Mar 31, 2026 came in at $6.04 million (quarter ended Dec 31, 2025), $6.74 million (quarter ended Sep 30, 2025) and $6.85 million (quarter ended Jun 30, 2025).